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doi:10.1016/j.jmii.2012.01.016Visceral leishmaniasis (VL) is a vector-borne protozoal infection caused by replication of Leish-
mania species in macrophages. VL is characterized by fever, hepatosplenomegaly and cytope-
nia. Apart from those classic clinical characteristics, VL has been associated with autoimmune
clinical and laboratory features. Reported herein are 16 consecutive patients with VL who
were checked for laboratory autoimmune manifestations. A variety of autoimmune antibodies
including elevated titers of antinuclear antibodies and rheumatoid factor were detected in all
patients. Of note, no laboratory autoimmune manifestations were detected in the seven
patients who were re-evaluated 3 months after therapy. It is concluded that autoimmune labo-
ratory manifestations during VL infection are common. These may mistakenly lead to diagnosis
of an autoimmune disorder.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Visceral leishmaniasis (VL) is a vector-borne protozoal
infection caused by replication of Leishmania species in
macrophages.1 There is a broad range of manifestations and
VL can even be asymptomatic or subclinical in some cases.
Classic clinical presentation of VL includes fever, abdominal
discomfort, weight loss, cough, pallor, splenomegaly and
hepatomegaly.2 Of note, splenomegaly may be absent inf Ioannina Medical School, 45
m (E. Liberopoulos).
an Society of Microbiology. Publimmunocompromised patients, or in the early stages of the
disease.3 Common laboratory findings include pancytopenia
and hypergammaglobulinemia.2 However, VL may present
with both clinical and laboratory autoimmune manifesta-
tions including arthralgia, cutaneous vasculitis, increased
titers of rheumatoid factor (RF), antinuclear antibodies
(ANAs), presence of cryoglobulins, and low serum comple-
ment levels.4e6 Of note, patients with VL who were initially
treated with corticosteroids have been described.7,8
The incidence of laboratory autoimmune manifestations
during VL infection remains unknown. In this study, we
checked 16 consecutive patients with VL for the presence
of laboratory autoimmune manifestations.ished by Elsevier Taiwan LLC. All rights reserved.
Leishmaniasis autoimmune manifestations 303Patients and methods
Consecutive hospitalized patients with VL (from August
2003 to April 2011) were studied. The study was approved
by the Ethics Committee of the University of Ioannina. VL
diagnosis was made by the presence of high titers of anti-
leishmania antibodies via indirect immunofluorescence
assay and indirect hemagglutination antibodies, as well as
demonstration of intracellular parasites on bone marrow
aspiration. All patients were negative for hepatitis B,
hepatitis C and human immunodeficiency viruses. All
patients were administered liposomal amphotericin B
(5 mg/kg/day on days 1e5, 14 and 21). On admission, ANA
(MB Laboratories, Sidney, BC, Canada), anti-smooth muscle
cell antibodies (Siemens Healthcare Diagnostics, Erlangen,
Germany), anti-neutrophil cytoplasmic antibodies (ANCAs),
including protoplasmic-staining and classical (MB Labora-
tories) were assessed by immunofluorescence. A commer-
cial enzyme-linked immunosorbent assay was used to
evaluate the levels of various autoantibodies including anti-
cardiolipin, anti-thyroid peroxidase, anti-thyroxine binding
globulin, anti-myeloperoxidase, anti-proteinase 3 (DRG
Instruments GmbH, Marburg, Germany), anti-extractable
nuclear antigen (ENA) (AESKU Diagnostics, Wendelsheim,
Germany), anti-Ro, anti-La and anti-double-stranded-DNA.
Anti-Smith (Sm) antibodies were evaluated via immuno-
printing (Inogenetics, Ghent, Belgium), while levels of
serum globulins, C3 and C4 fractions of complement and RF
were evaluated using nephelometry (Siemens Healthcare
Diagnostics, Erlangen, Germany). The presence of cry-
oglobulins and direct and indirect Coombs’ test were also
checked on admission. Seven patients were followed up and
re-evaluated 3 months after therapy.
All statistical analyses were carried out with SPSS
version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Sixteen consecutive patients (9 men and 7 women, aged
21e83 years) were studied (Table 1). No clinical autoim-
mune manifestations such as arthralgia or cutaneous
vasculitis were reported in any patient. Laboratory inves-
tigation revealed the presence of a broad spectrum ofTable 1 Patient characteristics on admission (n Z 16)a
Sex (M/F) 9/7
Age (y) 47.4  21.0
Weight (kg) 74.7  9
Smoking (yes/no) 8/8
Anti-leishmania antibody
titer (median, range)
IFA: 1/960
(1/160e1/10,240)
IHA: 1/384
(1/8e1/26,568)
Duration of fever before
hospitalization (d)
28  19
a Values are expressed as mean  standard deviation, except
for IFA and IHA which are expressed as median (range).
F Z female; IFA Z indirect fluorescent antibody;
IHA Z indirect hemagglutination antibody; M Z male.autoantibodies in all patients (Table 2). Specifically,
elevated titers of serum ANA were reported in 88% of
patients. Two patients also had elevated titers of anti-ENA
antibodies and two others had elevated titers of anti-ENA
and anti-Ro antibodies. It was noteworthy that neither
the titer of anti-leishmania antibodies (detected by
immunofluorescence assay and indirect hemagglutination
antibodies) nor the duration of fever was significantly
correlated with the increase in ANA titer (data not shown).
Elevated titers of serum RF were reported in 63% of
patients studied, whereas C3 and C4 factors of complement
were decreased in 13% and 50% of patients, respectively.
Hypergammaglobulinemia was revealed in 63% of patients;
in 60% of them, it was monoclonal, in 30%, polyclonal, and
in 10%, biclonal. In addition, in 50% of patients, serum
cryoglobulins were detected. Coombs’ direct test was
positive in one patient, whereas both direct and indirect
tests were positive in another patient. Other autoimmune
manifestations included the detection of anti-smooth
muscle cell antibodies (25%), protoplasmic ANCAs (25%),
and anti-myeloperoxidase (6%), anti-Sm (6%), anti-thyroid
peroxidase and anti-thyroxine binding globulin antibodies
(6%), whereas anti-double-stranded DNA and anti-
proteinase 3 antibodies were not detected in any patient.
Of note, no laboratory autoimmune manifestations were
detected in the seven patients who were re-evaluated
3 months after therapy.Discussion
All 16 consecutive patients with VL who were tested on
admission were found to have a variety of autoantibodies
present without any clinical autoimmune manifestation.
Elevated autoantibody titers subsided to normal levels 3
months after therapy in the seven patients who were
followed-up. The most common features of VL-associated
autoimmunity were elevated titers of ANA and RF.
VL infection has been occasionally associated with
autoimmune clinical and laboratory features.4e6 Small case
series have reported the presence of immunocomplexes,
complement consumption, and elevated RF levels in
approximately 80% of patients with VL.9,10 However, this is
believed to be the first time that autoimmune features
have been reported for all patients who were studied,
suggesting that autoimmune laboratory features may
universally characterize VL infection.
It has been suggested that VL infection may, especially
in patients with high parasitic load, stimulate T helper 2
lymphocytes to produce interleukins 4 and 10, which in turn
activate B cells to produce a wide spectrum of anti-
bodies.11,12 In contrast, Leishmania parasites themselves
may cause tissue destruction, releasing self antigens, which
in turn may stimulate autoreactivity.13 Especially for the
formation of cryoglobulins, a common mechanism between
hepatitis C and VL has been proposed, based on the
phenomenon of molecular mimicry.5 Patients with VL have
high titers of autoantibodies against a common epitope of
the lymphocyte activation gene 3 (LAG-3.1), whereas
patients with hepatitis C but no cryoglobulinemia do not
have any autoantibodies against this epitope.5 Of note,
molecular mimicry has been associated with the formation
Table 2 Immune laboratory findings on admissiona
Parameter (reference range)
ANA (<1/160) Elevated in 14 patients (88%): 1/480 (1/160e1/2560)
RF (<20 IU/mL) Elevated in 10 patients (63%): 42.7  35.9 IU/mL
C3 factor of complement (88e201 mg/dL) Decreased in 2 patients (13%)
1st patient: 38 mg/dL
2nd patient: 44 mg/dL
C4 factor of complement (16e47 mg/dL) Decreased in 8 patients (50%): 11.2  4.5 mg/dL
Anti-cardiolipin antibodies (IgG) Elevated in 2 patients (13%):
1st patient: 35 U/mL
2nd patient: 40 U/mL
Cryoglobulins Detected in 8 patients (50%)
Coombs’ test  Direct: positive in 2 patients (13%)
 Indirect: positive in 1 patient (6%)
b2-microglobulin (0e1900 mg/L) Elevated in 4 patients (25%): 37,900  23,800 mg/L
Hypergammaglobulinemia  Polyclonal: 3 patients (19%)
 Biclonal: 1 patient (6%)
 Monoclonal: 6 patients (38%)
ASMA Detected in 4 patients (25%) 1/160 (1/80e1/240)
p-ANCA Detected in 4 patients (25%) 1/40 (1/20e1/80)
Anti-TPO/anti-TBG Detected in 1 patient (6%)
Anti-ENA Detected in 4 patients (25%)
Anti-MPO Detected in 1 patient (6%)
Anti-Ro Detected in 2 patients (13%)
Anti-Sm Detected in 1 patient (6%)
Anti-ds-DNA Not detected (0%)
Anti-PR3 Not detected (0%)
a Values are expressed as mean  standard deviation, except for ANA, ASMA and p-ANCA, which are expressed as median (range).
ANAZ anti-nuclear antibody; anti-ds-DNAZ anti-double-stranded-DNA antibody; anti-ENAZ anti-extractable nuclear antigen antibody;
anti-MPO Z anti-myeloperoxidase antibody; anti-PR3 Z anti-proteinase 3 antibody; anti-Sm Z anti-Smith antibody; anti-TBG Z anti-
thyroxine binding globulin antibody; anti-TPO Z anti-thyroid peroxidase antibody; ASMA Z anti-smooth muscle cell antibody;
p-ANCAZ protoplasmic-staining anti-neutrophil cytoplasmic antibody; RFZ rheumatoid factor.
304 E. Liberopoulos et al.of a wide variety of lupus-related autoantibodies including
anti-nucleoprotein, anti-Ro, anti-La and anti-Sm.14 Thus,
the formation of autoantibodies during VL infection is
probably not only due to polyclonal B cell activation but
also to molecular mimicry between Leishmania antigens
and ribonucleoproteins.14
On practical grounds, it is important that patients with
VL can be initially misdiagnosed as having an autoimmune
disease (especially systemic lupus erythematosus),15 thus
potentially being treated with immunosuppressive drugs8
with even fatal consequences. Therefore, we should
always keep in mind that, especially in endemic areas, VL
has to be ruled out before starting immunosuppressive
drugs in patients with autoimmune laboratory manifesta-
tions. Moreover, VL should be considered in patients with
autoimmune disorders who do not respond to immunosup-
pressive treatment, because VL can mimic a flare of the
pre-existing autoimmune disease. This is especially true
when immunosuppressive treatment in these patients
provides the background on which VL may occur as an
opportunistic infection.6,16
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